0.95
price up icon0.81%   0.0076
 
loading
Schlusskurs vom Vortag:
$0.9424
Offen:
$0.9255
24-Stunden-Volumen:
30,848
Relative Volume:
0.17
Marktkapitalisierung:
$36.74M
Einnahmen:
$135.87M
Nettoeinkommen (Verlust:
$72.20M
KGV:
0.669
EPS:
1.42
Netto-Cashflow:
$45.09M
1W Leistung:
-4.42%
1M Leistung:
-7.77%
6M Leistung:
-33.57%
1J Leistung:
-34.48%
1-Tages-Spanne:
Value
$0.9255
$0.9771
1-Wochen-Bereich:
Value
$0.9255
$1.02
52-Wochen-Spanne:
Value
$0.8227
$3.07

Scynexis Inc Stock (SCYX) Company Profile

Name
Firmenname
Scynexis Inc
Name
Telefon
201-884-5485
Name
Adresse
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Name
Mitarbeiter
0
Name
Twitter
@scynexis
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
SCYX's Discussions on Twitter

Vergleichen Sie SCYX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
SCYX
Scynexis Inc
0.95 36.74M 135.87M 72.20M 45.09M 1.42
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
163.50 72.50B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.98 47.08B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.16 45.99B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
15.29 17.52B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
312.26 13.78B 2.76B 1.11B 898.10M 22.77

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-01-22 Eingeleitet Guggenheim Buy
2021-01-06 Eingeleitet Cantor Fitzgerald Overweight
2018-07-11 Hochstufung Needham Hold → Buy
2018-06-27 Eingeleitet Maxim Group Buy
2017-10-24 Eingeleitet Guggenheim Buy
2017-07-10 Eingeleitet ROTH Capital Buy
2017-05-09 Herabstufung Needham Buy → Hold
2017-03-03 Bestätigt RBC Capital Mkts Outperform
2016-10-20 Eingeleitet H.C. Wainwright Buy
2016-10-07 Hochstufung WBB Securities Buy → Strong Buy
2016-10-03 Fortgesetzt Brean Capital Buy
2016-08-17 Eingeleitet Guggenheim Buy
2016-08-09 Bestätigt Needham Buy
2016-08-09 Hochstufung WBB Securities Speculative Buy → Buy
2016-03-28 Eingeleitet Brean Capital Buy
2015-12-29 Eingeleitet WBB Securities Speculative Buy
2015-11-16 Bestätigt RBC Capital Mkts Outperform
2015-06-10 Eingeleitet Needham Buy
2014-05-29 Eingeleitet Canaccord Genuity Buy
2014-05-29 Eingeleitet RBC Capital Mkts Outperform
Alle ansehen

Scynexis Inc Aktie (SCYX) Neueste Nachrichten

pulisher
Mar 22, 2025

SCYNEXIS (NASDAQ:SCYX) Lowered to Sell Rating by StockNews.com - Defense World

Mar 22, 2025
pulisher
Mar 20, 2025

SCYNEXIS (SCYX) to Release Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 17, 2025

Research Analysts Issue Forecasts for SCYNEXIS FY2029 Earnings - Defense World

Mar 17, 2025
pulisher
Mar 15, 2025

StockNews.com Downgrades SCYNEXIS (NASDAQ:SCYX) to Sell - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

SCYNEXIS Full Year 2024 Earnings: Misses Expectations - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

SCYNEXIS Reports 2024 Financial Results and Updates - TipRanks

Mar 14, 2025
pulisher
Mar 12, 2025

Scynexis Inc earnings beat by $0.06, revenue fell short of estimates - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

Mar 12, 2025
pulisher
Mar 12, 2025

SCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study Restart - Nasdaq

Mar 12, 2025
pulisher
Mar 11, 2025

SCYX stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia

Mar 11, 2025
pulisher
Mar 05, 2025

NanoNewron Appoints Industry Veteran Marco Taglietti, M.D., as Chief Executive Officer to Lead the Company and the Development of Their Promising Alzheimer’s Compound - BioSpace

Mar 05, 2025
pulisher
Feb 26, 2025

EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of SCYNEXIS, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 8, 2017SCYX - ACCESS Newswire

Feb 26, 2025
pulisher
Feb 14, 2025

SCYNEXIS (NASDAQ:SCYX) Stock Crosses Below 200-Day Moving Average – Time to Sell? - Defense World

Feb 14, 2025
pulisher
Feb 02, 2025

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of SCYNEXIS, Inc. (SCYX) Investigation - ACCESS Newswire

Feb 02, 2025
pulisher
Jan 21, 2025

SCYNEXIS (NASDAQ:SCYX) Share Price Passes Below 200-Day Moving Average – Should You Sell? - Defense World

Jan 21, 2025
pulisher
Jan 12, 2025

Geode Capital Management LLC Acquires 36,405 Shares of SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jan 12, 2025
pulisher
Jan 08, 2025

FEDERATED HERMES, INC. Reduces Stake in SCYNEXIS Inc: A Detailed Analysis - GuruFocus.com

Jan 08, 2025
pulisher
Jan 06, 2025

Aspergillosis Market Expected to rise, 2034 | Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, I - The Globe and Mail

Jan 06, 2025
pulisher
Dec 30, 2024

SCYNEXIS, Inc. (NASDAQ:SCYX) Short Interest Update - Defense World

Dec 30, 2024
pulisher
Dec 20, 2024

Stay Ahead in Ophthalmology: Strategic Market Insights for Myopia Assessment & Forecasting | DelveInsight - GlobeNewswire Inc.

Dec 20, 2024
pulisher
Dec 20, 2024

SCYX stock touches 52-week low at $0.97 amid market challenges - Investing.com

Dec 20, 2024
pulisher
Dec 18, 2024

SCYNEXIS, Inc. Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections - Marketscreener.com

Dec 18, 2024
pulisher
Dec 18, 2024

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections - The Manila Times

Dec 18, 2024
pulisher
Dec 18, 2024

SCYNEXIS Launches Pivotal Phase 1 Trial for Novel Antifungal Drug Against Deadly Infections - StockTitan

Dec 18, 2024
pulisher
Dec 13, 2024

SCYX stock touches 52-week low at $1.15 amid market challenges - Investing.com Canada

Dec 13, 2024
pulisher
Dec 03, 2024

Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) & SCYNEXIS (NASDAQ:SCYX) - Defense World

Dec 03, 2024
pulisher
Nov 29, 2024

SCYNEXIS (NASDAQ:SCYX) adds US$6.5m to market cap in the past 7 days, though investors from five years ago are still down 86% - Simply Wall St

Nov 29, 2024
pulisher
Nov 15, 2024

Avidity Partners Management LP's Strategic Acquisition in SCYNEX - GuruFocus.com

Nov 15, 2024
pulisher
Nov 13, 2024

Federated Hermes, Inc. Increases Stake in SCYNEXIS Inc - GuruFocus.com

Nov 13, 2024
pulisher
Nov 11, 2024

SCYX stock touches 52-week low at $1.25 amid market challenges By Investing.com - Investing.com South Africa

Nov 11, 2024
pulisher
Nov 11, 2024

SCYX stock touches 52-week low at $1.25 amid market challenges - Investing.com

Nov 11, 2024
pulisher
Nov 08, 2024

SCYNEXIS announces new $50 million equity sales agreement By Investing.com - Investing.com Australia

Nov 08, 2024
pulisher
Nov 08, 2024

SCYNEXIS Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 08, 2024
pulisher
Nov 07, 2024

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Nov 07, 2024
pulisher
Nov 06, 2024

Scynexis Inc earnings beat by $0.08, revenue fell short of estimates - Investing.com Canada

Nov 06, 2024
pulisher
Nov 06, 2024

Scynexis: Q3 Earnings Snapshot - San Francisco Chronicle

Nov 06, 2024
pulisher
Nov 06, 2024

SCYNEXIS announces new $50 million equity sales agreement - Investing.com India

Nov 06, 2024
pulisher
Nov 06, 2024

SCYNEXIS Secures $10M GSK Milestone, Advances Antifungal Pipeline Despite Q3 Revenue Dip | SCYX Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 06, 2024

SCYNEXIS, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 06, 2024

Finanzdaten der Scynexis Inc-Aktie (SCYX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$10.77
price up icon 4.06%
$32.65
price up icon 0.37%
$97.42
price down icon 0.52%
$8.66
price up icon 0.70%
$108.31
price up icon 1.22%
$312.26
price up icon 1.75%
Kapitalisierung:     |  Volumen (24h):